<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10070885</article-id><article-id pub-id-type="pmc">2362650</article-id><article-id pub-id-type="pii">6690141</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690141</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jong</surname><given-names>R S de</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mulder</surname><given-names>N H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Uges</surname><given-names>D R A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sleijfer</surname><given-names>D Th</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>H&#x000f6;ppener</surname><given-names>F J P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Groen</surname><given-names>H J M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Willemse</surname><given-names>P H B</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Graaf</surname><given-names>W T A van der</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vries</surname><given-names>E G E de</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1">Department of Medical Oncology, University Hospital Groningen, Groningen, The Netherlands</aff><aff id="aff2">Department of Pharmacy and Toxicology, University Hospital Groningen, Groningen, The Netherlands</aff><aff id="aff3">Department of Pulmonary Diseases, University Hospital Groningen, Groningen, The Netherlands</aff><aff id="aff4">EORTC New Drug Development Office, Amsterdam, The Netherlands</aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>Department of Internal Medicine, Division of Medical Oncology, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands</corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>1999</year></pub-date><volume>79</volume><issue>5-6</issue><fpage>882</fpage><lpage>887</lpage><history><date date-type="received"><day>28</day><month>10</month><year>1997</year></date><date date-type="rev-recd"><day>10</day><month>08</month><year>1998</year></date><date date-type="accepted"><day>20</day><month>10</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>We conducted a phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. Fostriecin was administered intravenously over 60 min on days 1&#x02013;5 at 4-week intervals. Dose was escalated from 2 mg m<sup>&#x02212;2</sup>day<sup>&#x02212;1</sup>to 20 mg m<sup>&#x02212;2</sup>day<sup>&#x02212;1</sup>in 20 patients. Drug pharmacokinetics was analysed with high performance liquid chromatography with UV-detection. Plasma collected during drug administration was tested in vitro for growth inhibition of a teniposide-resistant small-cell lung cancer (SCLC) cell line. The predominant toxicities were elevated liver transaminases (maximum common toxicity criteria (CTC) grade 4) and serum creatinine (maximum CTC grade 2). These showed only a limited increase with increasing doses, often recovered during drug administration and were fully reversible. Duration of elevated alanine&#x02013;amino transferase (ALT) was dose-limiting in one patient at 20 mg m<sup>&#x02212;2</sup>. Other frequent toxicities were grade 1&#x02013;2 nausea/vomiting, fever and mild fatigue. Mean fostriecin plasma half-life was 0.36 h (initial; 95&#x00025; CI, 0&#x02013;0.76 h) and 1.51 h (terminal; 95&#x00025; CI, 0.41&#x02013;2.61 h). A metabolite, most probably dephosphorylated fostriecin, was detected in plasma and urine. No tumour responses were observed, but the plasma concentrations reached in the patients were insufficient to induce significant growth inhibition in vitro. The maximum tolerated dose (MTD) has not been reached, because drug supply was stopped at the 20 mg m<sup>&#x02212;2</sup>dose level. However, further escalation seems possible and is warranted to achieve potentially effective drug levels. Fostriecin has a short plasma half-life and longer duration of infusion should be considered. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>fostriecin</kwd><kwd>topoisomerase II</kwd><kwd>phase I</kwd><kwd>pharmacokinetics</kwd></kwd-group></article-meta></front></article>
